InfuSystem (NYSE:INFU) Upgraded at StockNews.com

StockNews.com upgraded shares of InfuSystem (NYSE:INFU) from a buy rating to a strong-buy rating in a research note issued to investors on Friday morning.

InfuSystem Stock Performance

NYSE INFU opened at $5.55 on Friday. InfuSystem has a 1 year low of $5.28 and a 1 year high of $9.97. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.98 and a quick ratio of 1.59. The stock has a market capitalization of $116.60 million, a PE ratio of 92.52 and a beta of 1.75. The company’s 50 day simple moving average is $7.65 and its two-hundred day simple moving average is $7.57.

Institutional Trading of InfuSystem

Several institutional investors and hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets lifted its stake in InfuSystem by 66.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock worth $27,000 after purchasing an additional 1,626 shares in the last quarter. Barclays PLC raised its position in shares of InfuSystem by 10.1% during the 4th quarter. Barclays PLC now owns 31,479 shares of the company’s stock valued at $266,000 after buying an additional 2,882 shares in the last quarter. State Street Corp raised its position in shares of InfuSystem by 1.1% during the 3rd quarter. State Street Corp now owns 267,012 shares of the company’s stock valued at $1,789,000 after buying an additional 3,019 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of InfuSystem by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 9,286 shares of the company’s stock valued at $78,000 after buying an additional 3,165 shares in the last quarter. Finally, Millennium Management LLC raised its position in shares of InfuSystem by 6.3% during the 4th quarter. Millennium Management LLC now owns 76,419 shares of the company’s stock valued at $646,000 after buying an additional 4,532 shares in the last quarter. 71.13% of the stock is currently owned by hedge funds and other institutional investors.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.